Get started
Author

Katherine Karakasis

Observed names: K Karakasis, K. Karakasis, Karakasis, Katherine
OpenAlex ID: A5038405310
Outcomes and endpoints in trials of cancer treatment: the past, present, and future
2014 · Michelle K Wilson, Katherine Karakasis, et al. · The Lancet Oncology · 230
Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial
2021 · Stephanie Lheureux, Mihaela C Cristea, et al. · The Lancet · 221
Overcoming Platinum and PARP-Inhibitor Resistance in Ovarian Cancer
2020 · Michelle McMullen, Katherine Karakasis, et al. · Cancers · 199
PDF
Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus–Related Cervical Carcinoma
2017 · Stephanie Lheureux, Marcus O. Butler, et al. · JAMA Oncology · 158
PDF
Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization
2017 · Stephanie Lheureux, Zhongwu Lai, et al. · Clinical Cancer Research · 153
PDF
EVOLVE: A Multicenter Open-Label Single-Arm Clinical and Translational Phase II Trial of Cediranib Plus Olaparib for Ovarian Cancer after PARP Inhibition Progression
2020 · Stephanie Lheureux, Ana Oaknin, et al. · Clinical Cancer Research · 134
Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long- and short-term survivors
2018 · S. Y. Cindy Yang, Stephanie Lheureux, et al. · Genome Medicine · 108
PDF
Outcomes and endpoints in cancer trials: bridging the divide
2014 · Michelle K Wilson, Deborah Collyar, et al. · The Lancet Oncology · 97
Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition
2017 · Stephanie Lheureux, Jeff P. Bruce, et al. · Journal of Clinical Oncology · 92
Updates on systemic therapy for cervical cancer
2021 · Paul Gopu, Febin Antony, et al. · The Indian Journal of Medical Research · 79
Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer
2013 · Helen J. Mackay, Elizabeth A. Eisenhauer, et al. · Cancer · 76
Advances in ovarian cancer, from biology to treatment
2021 · Michelle McMullen, Katherine Karakasis, et al. · Nature Cancer · 67
Chasing Immune Checkpoint Inhibitors in Ovarian Cancer: Novel Combinations and Biomarker Discovery
2023 · Ilaria Colombo, Katherine Karakasis, et al. · Cancers · 47
PDF
TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analyses
2019 · Victoria Mandilaras, Swati Garg, et al. · International Journal of Gynecological Cancer · 45
Ovarian cancer treatment: The end of empiricism?
2015 · Stephanie Lheureux, Katherine Karakasis, et al. · Cancer · 41
PDF
Progression-Free Survival in Advanced Ovarian Cancer: A Canadian Review and Expert Panel Perspective
2011 · A. M. Oza, V. Castonguay, et al. · Current Oncology · 36
PDF
Optimizing the Care of Malignant Bowel Obstruction in Patients With Advanced Gynecologic Cancer
2019 · Yeh Chen Lee, Nazlin Jivraj, et al. · Journal of Oncology Practice · 31
Updates and current challenges in microRNA research for personalized medicine in ovarian cancer
2017 · Victoria Mandilaras, Mégane Vernon, et al. · Expert Opinion on Biological Therapy · 25
Uncovering a Link between a Plastid Translocon Component and Rhomboid Proteases Using Yeast Mitochondria-Based Assays
2007 · Katherine Karakasis, Darcie Taylor, et al. · Plant and Cell Physiology · 24
Measuring Quality of Life in Ovarian Cancer Clinical Trials—Can We Improve Objectivity and Cross Trial Comparisons?
2020 · Gita Bhat, Katherine Karakasis, et al. · Cancers · 23
PDF
A phase I/II study of ipilimumab in women with metastatic or recurrent cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia.
2015 · Stephanie Lheureux, Marcus O. Butler, et al. · Journal of Clinical Oncology · 20
Ovarian Cancer and BRCA1/2 Testing: Opportunities to Improve Clinical Care and Disease Prevention
2016 · Katherine Karakasis, Julia V. Burnier, et al. · Frontiers in Oncology · 18
PDF
Safety evaluation of olaparib for treating ovarian cancer
2015 · Stephanie Lheureux, Valerie Bowering, et al. · Expert Opinion on Drug Safety · 18
Rare tumors in gynaecological cancers and the lack of therapeutic options and clinical trials
2016 · Victoria Mandilaras, Katherine Karakasis, et al. · Expert Opinion on Orphan Drugs · 17
New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?
2016 · Victor Rodriguez-Freixinos, Katherine Karakasis, et al. · Current Oncology Reports · 15
Works count: 82
Citation count: 2,122
H-index: 20
I10-index: 31
Year
Topic
Type